Amneal Pharmaceuticals, Inc. 4

Insider John Kiely had 34,819 RSUs vest into Class A Common Stock and received a new grant of 19,824 RSUs in Amneal Pharmaceuticals, Inc.

On this Form 4, insider John Kiely reported equity compensation-related activity in Amneal Pharmaceuticals, Inc. On May 7, 2026, 34,819 restricted stock units (RSUs) previously granted on May 6, 2025 vested and were converted into 34,819 shares of Class A Common Stock, with his direct common stock ownership increasing from 225,433 shares to 260,252 shares. Correspondingly, his RSU balance decreased by 34,819 units, reflecting the settlement of those RSUs into common stock. In addition, a new award of 19,824 restricted stock units was reported on May 6, 2026, which represents a fresh grant of equity compensation that will vest based on the company’s standard vesting schedule. No open‑market purchases or sales were disclosed, and all movements stem from routine equity award vesting and grants.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032911

Alert Tier

5